Multiple generation ALK-tyrosine kinase inhibitors (TKIs) have been developed to target ALK mutations, and most of them have been established as the standard-of-care globally in treating advanced ALK-positive NSCLC globally (5). Here, ALK is linked to non-small cell lung carcinoma.